Home  >  News
Msc_Apr23 .
you can get e-magazine links on WhatsApp. Click here
  Xilio Therapeutics initiates enrollment in phase 1 trial of tumour-activated, Fc-enhanced anti-CTLA-4, XTX101 in combo with atezolizumab,   December 09, 2023
  Bristol Myers Squibb announces phase 3 CheckMate -8HW trial of Opdivo plus Yervoy compared to chemotherapy in MSI-H or dMMR mCRC meets dual primary endpoint,   December 09, 2023
  Merck to discontinue phase 3 KEYLYNK-008 trial of Keytruda plus Lynparza to treat metastatic squamous NSCLC,   December 09, 2023
  Hansa Biopharma announces positive results from 15-HMedIdeS-09 phase 2 trial of imlifidase to treat Guillain-BarrĂ© syndrome,   December 08, 2023
  Sanofi announces phase 3 IMROZ trial of Sarclisa in combo with bortezomib, lenalidomide & dexamethasone meets primary endpoint of PFS in patients with newly diagnosed MM,   December 08, 2023
  Merck announces positive results from phase 2 KeyVibe-002 trial evaluating coformulation of vibostolimab and pembrolizumab in previously treated patients with metastatic NSCLC,   December 08, 2023
  Enveric selects development candidates from EVM301 Series based on potential to minimize or eliminate the hallucinogenic effect of psychedelic-derived compounds,   December 07, 2023
  NIH-supported study shows surgery beneficial for some children with mild sleep-disordered breathing,   December 07, 2023
  Exelixis initiates STELLAR-305 phase 2/3 pivotal trial of zanzalintinib in combo with pembrolizumab in patients with previously untreated recurrent or metastatic SCCHN,   December 06, 2023
  Roche announces positive results from phase III INAVO120 study of inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation,   December 06, 2023
  UK MHRA grants CTA for Mission Therapeutics to begin phase 1 study of MTX325 to treat Parkinson’s disease,   December 06, 2023
  Exelixis, Arcus Biosciences enter clinical trial collaboration to evaluate zanzalintinib in combo with AB521 in patients with advanced RCC,   December 05, 2023
  Sana Biotechnology announces early clinical data of SC291, a CD19-directed allogeneic CAR T cell therapy,   December 05, 2023
  Foghorn Therapeutics to present clinical data from phase 1 study of FHD-286 at ASH Annual Meeting in San Diego,   December 05, 2023
  Telix begins patient dosing in Netherlands for PET imaging agent, TLX250-CDx to treat kidney cancer,   December 05, 2023
  SciSparc's obesity drug showed positive results in a pre-clinical trial,   December 04, 2023
  Pfizer reports positive results from phase 2b trial of oral GLP-1R agonist, danuglipron in adults with obesity,   December 04, 2023
  Daiichi Sankyo demonstrates breadth and depth of oncology portfolio across multiple cancers with new data at ESMO Asia, SABCS & ASH,   December 02, 2023
  First WHO Global Clinical Trials Forum puts forward a global vision for sustainable clinical research infrastructure,   December 02, 2023
  AstraZeneca to discontinue STABILIZE-CKD and DIALIZE-Outcomes phase III trials for Lokelma,   December 02, 2023

Pharma live expo
Close Open
Copyright © 2023 Saffron Media Pvt. Ltd |